Skip to content
PPepIndex

Evidence digest

What the research on CJC-1295 actually shows

The indexed literature on CJC-1295 includes human clinical or observational records (2 human-clinical or observational records). This digest describes the shape of that evidence and links the records behind it. It does not judge whether CJC-1295 is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.

Updated 25 Aug 2026 · 2 studies indexed · 2 human · compound record

Studies indexed
2
Human evidence
2
Preclinical only
0

What is and is not established

What the literature supports

  • Human clinical or observational records are indexed for CJC-1295 (2).
  • Published research is indexed back to 2005, with roughly 32 PubMed records located.
  • It is listed by one or more vendors tracked in this index.

What is NOT established

  • This index does not evaluate whether CJC-1295 is safe or effective for any use.
  • Material sold by the vendors indexed here is labeled for laboratory research use only and is not a regulator-approved medicine in that form.
  • No dosing, protocol or human-use guidance is provided or implied anywhere in this index.

Studies indexed

2 human — controlled trial
Each row links to that study's permalink, where every digest citing it is listed. Findings are reported as the paper reported them — an animal result is not restated as a human one.
StudyEvidence typeModelnWhat it reportedSource
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adultsThe Journal of clinical endocrinology and metabolism · 2006Human — controlled trialNot recorded—Therapeutic use of GHRH to enhance GH secretion is limited by its short duration of action. The objective of this study was to examine the pharmacokinetic profile, pharmacodynamic effects, and safety of CJC-1295, a long-acting GHRH analog. The study design was two randomized, placebo-controlled, double-blind, ascending dose trials with durations of 28 and 49 d. The study was performed at two investigational sites. Healthy subjects, ages 21-61 yr, were studied. CJC-1295 or pla…PMID 16352683
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analogThe Journal of clinical endocrinology and metabolism · 2006Human — controlled trialNot recorded—Pulsatile GH secretion is considered important for many of the hormone's physiological effects. Short-term GHRH infusions enhance GH pulsatility and increase IGF-I, but the short GHRH half-life limits its therapeutic use. A synthetic GHRH analog (CJC-1295) that binds permanently to endogenous albumin after injection (half-life = 8 d) stimulates GH and IGF-I secretion in several animal species and in normal human subjects and enhances growth in rats. Our objective was to asses…PMID 17018654

Regulatory status

Full feed →
FDACompounding list

FDA bulk drug substances nominated for compounding — 503A and 503B lists

Placeholder seed entry recording the source, not an event. The FDA maintains categorised lists of bulk drug substances nominated for use in compounding, including substances it has evaluated and placed in the category that may not be compounded. Several peptides tracked in this index have appeared in these evaluations. PepIndex records movements between categories here as they are observed; the linked page is the authoritative listing.

SemaglutideBPC-157IpamorelinCJC-1295

WADAProhibited list

WADA Prohibited List — growth factors and peptide hormones (class S2)

Placeholder seed entry recording the source, not an event. The World Anti-Doping Agency publishes an annual Prohibited List; class S2 covers peptide hormones, growth factors, related substances and mimetics. Several compounds tracked in this index fall within that class or its catch-all clause. The list is revised annually and takes effect on 1 January. PepIndex records revisions affecting indexed compounds here.

IpamorelinCJC-1295TB-500

Vendors listing CJC-1295

Ranked view →

The evidence above describes the published literature. What any individual vial contains is a separate question, answered by that vendor’s certificate records rather than by any study on this page.

VendorScore · CoverageCertificates
Curo93.877%1profile →
Ascend Science90.291%2profile →
Hydro Research Peptides88.289%0profile →
Protide Health83.994%0profile →
American Peptides83.6100%0profile →
Northline Labs79.493%2profile →
NeuroLabs Research79.386%0profile →
ZC Labs79.384%0profile →
Good Science Bio79.275%0profile →
Ascension Peptides78.186%2profile →
Licensed Peptides7789%1profile →
Modern Aminos74100%2profile →
Simple Peptide7489%2profile →
GenX Peptides70.868%0profile →
Improved Peptides7089%0profile →
Eternal Peptides68.265%0profile →
Evolve Peptides65.567%0profile →
Mile High Compounds65.494%0profile →
Extreme Peptides64.282%0profile →

How to read this page

This digest describes what published research exists and what it does not establish. It is not a recommendation, contains no dosing information or protocols, and makes no claim that any compound is safe or effective for any purpose. Material listed by indexed vendors is labeled for laboratory research use only.